Study Overview

This study investigates the safety, tolerability and effectiveness of daily peanut oral immunotherapy treatment in children 1 to 3 years of age over the course of approximately 1 year. The total duration of the study is approximately 24 months. Compensation will be provided.

Study Eligibility

Must be between 1 and 3 years of age, and have a physician documented peanut allergy.


For more information, contact the Allergy Research Group 501-364-3031.